DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jun 11, 2025
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-06-09$19.39/sh+82,500$1,599,675→ 82,500 totalExercise: $19.39Exp: 2035-06-09→ Common Stock (82,500 underlying)
Footnotes (1)
- [F1]This represents stock option award granted on June 9, 2025, which will vest over a two-year period. Specifically, 50% of the options will vest on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.